Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
Statistical Analysis for Comparing Antifracture Efficacy among Antiresorptive Agents: Alendronate versus Alfacalcidol and Calcitonin.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- معلومة اضافية
- نبذة مختصرة :
Objective: To develop a method that estimates and compares the antifracture efficacy [relative risk reduction (RRR) and number needed to treat (NNT)] of various antiresorptive agents when fracture trials are not available. Design, Setting and Patients: Statistical analysis using efficacy data from clinical trials of postmenopausal women with osteoporosis. Interventions: Oral alendronate 5mg, oral alfacalcidol 1µg, or intranasal calcitonin 200IU daily. Methods: We used the effects on bone mineral density (BMD) in head-to-head trials together with the relationship between BMD changes and fracture risk reductions reported in published meta-analyses of antifracture trials to predict and compare RRR and NNT. Results: The predicted RRR was similar to the published values in large clinical trials, thus validating the method. With an incidence of 12% over 3 years in untreated women with pre-existing vertebral fractures (based on a large epidemiological study), the predicted NNT to prevent a new vertebral fracture was 17 for alendronate and 29 for alfacalcidol; similar results were observed for alendronate versus calcitonin. For nonvertebral fractures, the NNT was three to four times lower for alendronate, compared with alfacalcidol and calcitonin. Conclusions: There is currently insufficient evidence of antifracture efficacy from randomised trials to recommend the use of alfacalcidol or calcitonin for treating osteoporosis. Furthermore, our analyses indicate that alendronate is substantially more effective for reducing vertebral and nonvertebral fracture risk than alfacalcidol or calcitonin. [ABSTRACT FROM AUTHOR]
- نبذة مختصرة :
Copyright of Clinical Drug Investigation is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
No Comments.